Immunic announces completion of enrollment for both phase 3 ensure trials in relapsing ms and presents additional data underlining positive outcome of phase 2 calliper trial in progressive ms

– enrollment completed for both phase 3 ensure trials of vidofludimus calcium in relapsing multiple sclerosis; top-line data expected end of 2026 – – additional data from phase 2 calliper trial in progressive multiple sclerosis further supports the recently released positive top-line results and further underlines vidofludimus calcium's neuroprotective potential – – new calliper data regarding time to 24-week confirmed disability worsening shows substantial and medically relevant reductions for vidofludimus calcium over placebo in the overall study population and major disease subtypes – new york , june 5, 2025 /prnewswire/ -- immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced the completion of enrollment for both phase 3 ensure trials of lead asset, nuclear receptor-related 1 (nurr1) activator, vidofludimus calcium (imu-838), in patients with relapsing multiple sclerosis and additional phase 2 calliper trial data in patients with progressive multiple sclerosis underlining the recently released positive top-line results. enrollment completed for both phase 3 ensure trials in relapsing multiple sclerosis (rms) the ensure program comprises two identical multicenter, randomized, double-blind phase 3 trials designed to evaluate the efficacy, safety and tolerability of vidofludimus calcium versus placebo in rms patients.
IMUX Ratings Summary
IMUX Quant Ranking